INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 194 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is 1.35 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $281,373 | -0.2% | 17,294 | 0.0% | 0.00% | – |
| Q4 2021 | $282,000 | +9.7% | 17,294 | 0.0% | 0.00% | – |
| Q3 2021 | $257,000 | -90.0% | 17,294 | -86.5% | 0.00% | -100.0% |
| Q2 2021 | $2,558,000 | +11.9% | 128,071 | +29.3% | 0.00% | 0.0% |
| Q1 2021 | $2,286,000 | -52.2% | 99,035 | -48.9% | 0.00% | 0.0% |
| Q4 2020 | $4,782,000 | -32.8% | 193,621 | +12.9% | 0.00% | -50.0% |
| Q3 2020 | $7,112,000 | -40.3% | 171,545 | -31.0% | 0.00% | -33.3% |
| Q2 2020 | $11,916,000 | -40.9% | 248,708 | -22.3% | 0.00% | -57.1% |
| Q1 2020 | $20,161,000 | -46.1% | 320,216 | +6.0% | 0.01% | -30.0% |
| Q4 2019 | $37,422,000 | +86.7% | 301,988 | 0.0% | 0.01% | +66.7% |
| Q3 2019 | $20,040,000 | -16.6% | 301,988 | 0.0% | 0.01% | -14.3% |
| Q2 2019 | $24,029,000 | -23.8% | 301,988 | +7.1% | 0.01% | -30.0% |
| Q1 2019 | $31,549,000 | +11.0% | 282,045 | 0.0% | 0.01% | -9.1% |
| Q4 2018 | $28,428,000 | -20.2% | 282,045 | 0.0% | 0.01% | -8.3% |
| Q3 2018 | $35,639,000 | +126.2% | 282,045 | +50.2% | 0.01% | +140.0% |
| Q2 2018 | $15,756,000 | +647.4% | 187,769 | +448.0% | 0.01% | +400.0% |
| Q1 2018 | $2,108,000 | +124.5% | 34,265 | +113.3% | 0.00% | – |
| Q4 2017 | $939,000 | +0.8% | 16,065 | 0.0% | 0.00% | – |
| Q3 2017 | $932,000 | +38.5% | 16,065 | +189.1% | 0.00% | – |
| Q2 2017 | $673,000 | -91.7% | 5,557 | -92.3% | 0.00% | -100.0% |
| Q1 2017 | $8,130,000 | -53.9% | 71,881 | -55.8% | 0.00% | -62.5% |
| Q4 2016 | $17,652,000 | -20.6% | 162,465 | +14.9% | 0.01% | -27.3% |
| Q3 2016 | $22,223,000 | +28.7% | 141,367 | +16.8% | 0.01% | +37.5% |
| Q2 2016 | $17,266,000 | +59.0% | 121,012 | +43.2% | 0.01% | +60.0% |
| Q1 2016 | $10,860,000 | -40.8% | 84,531 | -31.2% | 0.01% | -44.4% |
| Q4 2015 | $18,351,000 | -10.0% | 122,873 | 0.0% | 0.01% | -18.2% |
| Q3 2015 | $20,380,000 | -34.1% | 122,873 | -4.1% | 0.01% | -26.7% |
| Q2 2015 | $30,934,000 | -14.4% | 128,155 | 0.0% | 0.02% | -16.7% |
| Q1 2015 | $36,142,000 | +88.2% | 128,155 | +4.1% | 0.02% | +80.0% |
| Q4 2014 | $19,201,000 | -34.1% | 123,083 | 0.0% | 0.01% | -37.5% |
| Q3 2014 | $29,132,000 | -50.0% | 123,083 | -50.0% | 0.02% | 0.0% |
| Q2 2014 | $58,250,000 | +376.3% | 246,166 | +563.8% | 0.02% | +128.6% |
| Q1 2014 | $12,230,000 | – | 37,083 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |